OSE Immunotherapeutics — Reaffirmed dedication to core assets
OSE Immunotherapeutics has reaffirmed its strategy of streamlining its clinical pipeline following some developments to its partnered assets. For...
163 Views
OSE Immunotherapeutics — Renewed focus on advancing core assets
We revisit our investment case for OSE Immunotherapeutics following the recently presented strategic plans for 2026–28, reflecting a more...
242 Views
OSE Immunotherapeutics — Strategic plan presented for 2026–2028
OSE has announced its strategic plan for the next three years, which is designed to create multiple near-term catalysts. Importantly, it aims to...
226 Views
OSE Immunotherapeutics — Refocusing for the next phase
OSE Immunotherapeutics’ H125 results, the first since the board restructuring, reflected normalised operations typical of a clinical-stage biotech,...
249 Views
OSE Immunotherapeutics — Updated cash position; new collaboration
While OSE Immunotherapeutics’ H125 results were previously due to be presented in September, they are now scheduled for 15 October 2025 to allow...
437 Views